PEPGEN INC. (PEPG) Free cash flow
- Free cash flow · 12 months (USD): Value $-69.46M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-69.46M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-69.34M − $126.00K ≈ $-69.46M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-69.34M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.96× | Operating cash flow / net income. Period ending 2026-06-30. $-69.34M ÷ $-71.94M ≈ 0.96× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -69.34M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 126.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -69.46M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -71.94M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-69.46M | (m) | $-69.34M | $126.00K | (m) | (m) | (m) | $-71.94M | (m) | (m) | (m) | 0.96× |
| 2026-03-31 | $-77.27M | (m) | $-77.13M | $139.00K | (m) | (m) | (m) | $-77.22M | (m) | (m) | (m) | 1.00× |
| 2025-12-31 | $-81.90M | (m) | $-81.64M | $264.00K | (m) | (m) | (m) | $-89.66M | (m) | (m) | (m) | 0.91× |
| 2025-09-30 | $-85.76M | (m) | $-85.27M | $493.00K | (m) | (m) | (m) | $-93.56M | (m) | (m) | (m) | 0.91× |
| 2025-06-30 | $-90.60M | (m) | $-90.02M | $581.00K | (m) | (m) | (m) | $-96.92M | (m) | (m) | (m) | 0.93× |
| 2025-03-31 | $-83.34M | (m) | $-82.77M | $569.00K | (m) | (m) | (m) | $-102.16M | (m) | (m) | (m) | 0.81× |
| 2024-12-31 | $-82.87M | (m) | $-82.37M | $497.00K | (m) | (m) | (m) | $-89.98M | (m) | (m) | (m) | 0.92× |
| 2024-09-30 | $-82.77M | (m) | $-82.32M | $453.00K | (m) | (m) | (m) | $-87.23M | (m) | (m) | (m) | 0.94× |
| 2024-06-30 | $-75.49M | (m) | $-74.99M | $493.00K | (m) | (m) | (m) | $-89.14M | (m) | (m) | (m) | 0.84× |
| 2024-03-31 | $-77.58M | (m) | $-76.11M | $1.47M | (m) | (m) | (m) | $-80.33M | (m) | (m) | (m) | 0.95× |
| 2023-12-31 | $-71.60M | (m) | $-69.00M | $2.60M | (m) | (m) | (m) | $-78.63M | (m) | (m) | (m) | 0.88× |
| 2023-09-30 | $-66.48M | (m) | $-62.96M | $3.52M | (m) | (m) | (m) | $-74.07M | (m) | (m) | (m) | 0.85× |
| 2023-06-30 | $-71.17M | (m) | $-67.45M | $3.72M | (m) | (m) | (m) | $-69.38M | (m) | (m) | (m) | 0.97× |
| 2023-03-31 | $-65.74M | (m) | $-62.41M | $3.32M | (m) | (m) | (m) | $-67.18M | (m) | (m) | (m) | 0.93× |
| 2022-12-31 | $-63.02M | (m) | $-59.27M | $3.75M | (m) | (m) | (m) | $-69.10M | (m) | (m) | (m) | 0.86× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-23.10M | (m) | $-22.60M | $500.00K | (m) | (m) | (m) | $-27.28M | (m) | (m) | (m) | 0.83× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |